The research department at Dayton Center for Neurological Disorders was started in 2013. Since then, we have been actively involved in several prominent research studies related to Multiple Sclerosis, Parkinson’s Disease, and Alzheimer’s Disease. Call 937-424-3033 for more information.
It’s all about getting answers. DCND is committed to furthering science and medicine and helping patients. Getting involved in research can help the medical community develop new drugs and treatments that improve the quality of life for patients. The overall goal is to know as much as we can about a disease so we can better treat it.
By getting involved in research, you can help others in the same situation and possibly get access to cutting edge treatment not available for everyone yet.
What we are currently looking for:
- Diagnosed with multiple sclerosis
- Newly prescribed Gilenya
- Willing to have dermatology exams
- Never treated with Tysabri
- Have a diagnosis of relapsing remitting multiple sclerosis
- Currently in an acute exacerbation
- Planning to initiate Acthar Gel for the treatment of acute exacerbation
- Have a diagnosis of multiple sclerosis
- Newly prescribed Tecfidera
- Never treated with Tecfidera previously
Looking for people who have mild Alzheimer’s Disease, or memory or thinking problems that may be early symptoms of Alzheimer’s Disease.
CREAD 2 is a clinical research study for people aged 50-85 with early Alzheimer’s.
PATIENT ELIGIBILITY CRITERA:
- Age 50 years old to 85 years
- MMSE =/> 22
- Willing to provide informed written consent
- Have a study partner
Interested? Call 937-424-3033
- Diagnosed with Parkinson’s disease
- Experience symptoms of illusions, a false sense of presence, hallucinations, and/or delusions
- Have a caregiver willing to also participate
- Diagnosed with symptomatic orthostatic hypotension
- Able to stand with or without limited assistance
- Untreated closed angle glaucoma
- Diagnosis of hypertension that requires treatment with antihypertensive medications (short-acting antihypertensives to treat nocturnal supine hypertension are allowed in this study)
- Any significant uncontrolled cardiac arrhythmia
- History of myocardial infarction or stroke within the past 2 years
- Current unstable angina
- Congestive heart failure (NYHA Class 3 or 4)
- Diabetic autonomic neuropathy
- History of cancer within the past 2 years other than a successfully treated, non-metastatic cutaneous squamous cell or basal cell carcinoma or cervical cancer.